Shire PLC (SHPG) Receives Buy Rating from Cantor Fitzgerald
Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reiterated by Cantor Fitzgerald in a research note issued on Thursday. They presently have a $222.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 40.63% from the stock’s previous close.
SHPG has been the topic of several other reports. BidaskClub cut Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Friday, June 16th. HSBC Holdings plc cut Shire PLC from a “hold” rating to a “reduce” rating in a research report on Friday, May 19th. Barclays PLC cut Shire PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. Sanford C. Bernstein cut Shire PLC from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $209.22 to $161.09 in a research report on Thursday, May 25th. Finally, Evercore ISI initiated coverage on Shire PLC in a report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $220.08.
Shares of Shire PLC (NASDAQ SHPG) traded up 0.61% during trading on Thursday, reaching $158.79. The company’s stock had a trading volume of 2,515,171 shares. The firm has a market cap of $47.30 billion, a P/E ratio of 71.05 and a beta of 1.61. The stock’s 50 day moving average is $153.73 and its 200 day moving average is $168.99. Shire PLC has a one year low of $139.36 and a one year high of $209.22.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. On average, equities analysts forecast that Shire PLC will post $14.93 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/15/shire-plc-shpg-receives-buy-rating-from-cantor-fitzgerald.html.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Maverick Capital Ltd. raised its stake in Shire PLC by 19.9% during the 2nd quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock valued at $320,969,000 after purchasing an additional 322,610 shares during the period. Glenview Capital Management LLC raised its stake in Shire PLC by 69.7% during the 2nd quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock valued at $284,756,000 after purchasing an additional 707,500 shares during the period. Vanguard Group Inc. raised its stake in Shire PLC by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after purchasing an additional 13,665 shares during the period. Ameriprise Financial Inc. raised its stake in Shire PLC by 14.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock valued at $249,577,000 after purchasing an additional 194,059 shares during the period. Finally, BlackRock Inc. raised its stake in Shire PLC by 4,217.7% during the 1st quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after purchasing an additional 1,400,275 shares during the period. 19.13% of the stock is currently owned by institutional investors.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.